For further information, please contact:
Tel: +1 360 682 4247
ROHNERT PARK, CA, February 13, 2015 — IDEX Health & Science, LLC (IH&S), a division of IDEX Corporation’s (NYSE:IEX) Health & Science Technologies, announces its segmentation into two distinct businesses: Analytical Instruments and In Vitro Diagnostics / Biotechnology. The structural realignment of IDEX Health & Science into two market-specific sectors will drive growth and better serve customers in their respective end-markets.
Greg Orr has been named VP/GM of the Analytical Instrument (AI) business. This sector will combine global research & development, engineering, and commercial resources to focus on new OEM platforms and consumable/aftermarket products. The Analytical Instruments business will serve the non-clinical analytical instrument market.
Joe Rytell has been appointed VP/GM of the In Vitro Diagnostics and Biotech (IVD/Biotech) business. This sector will combine global research & development, engineering, and commercial resources to focus on IVD core-lab, next generation DNA sequencing, molecular diagnostics, and professional point-of-care. The IVD/Biotech business will organize IH&S activity into one group that serves clinical OEM instrumentation manufacturers.
IDEX Health & Science manufacturing has also been realigned with a focus on operational excellence in producing products for these markets. Keith Andrews has been named Regional Operations Director for the Rohnert Park and Oak Harbor sites. Chad Collins has also been named Regional Operations Director and will manage the Middleboro and Bristol facilities. Yoshio Ishii will continue to provide leadership to the ERC site in Saitama, Japan.
This newly announced business segmentation is intended to accelerate product innovation, betterleverage the full suite of IDEX Health & Science products and technology, and enhance the overall customer experience as a result of dedicated, market-focused teams and simplified reporting structures.
Greg Orr has been with IDEX Health & Science for over 20 years. As general manager of the Rohnert Park facility from 2008 to 2015, Orr oversaw the development and manufacturing of valve and degasser products for the analytical instrument market. He also helped facilitate the acquisition and integration of the ERC business unit in Saitama, Japan in 2012. Orr began his career with IDEX Health & Science as the VP of sales and marketing and president for the Trebor business unit, which serves the semiconductor manufacturing equipment market. Orr received his BA in Finance and MBA from the University of Utah. He will remain based in Rohnert Park, California.
Joe Rytell has invested over 24 years in the healthcare and life sciences markets. He joined IDEX Health & Science in 2012 as the VP of Global Sales & Marketing. Previously, Rytell served as VP of Sales at Astellas Pharma, and VP of US Sales at Abbott Laboratories’ Diagnostics Division. At Abbott, Rytell led a sales force selling in vitro diagnostics instruments, reagents, and consumables to hospital and reference laboratories, as well as blood banks. Rytell received his BS in Business Administration at Bucknell University. He will remain based in Lake Forest, Illinois.
IDEX Health & Science offers a three-fold advantage to its customers by bringing life to fluidic pathways with products, people, and engineering expertise. These integrated assets work seamlessly together to enable fluidic pathways beyond a combination of components, which collectively position IDEX Health & Science as the forerunner in biotechnology and life science fluidics. Known as industry leaders in the design, development, and manufacturing of liquid subassemblies, fluidic products and related sub-systems, IDEX Health & Science provides the best solution for analytical, diagnostic, and biotech instruments. Product offerings include: fluidic connections, valves, pumps, degassers, column hardware, manifolds, and customized assemblies. For more information visit: www.idex-hs.com